Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | PEPD | P12955 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3151603 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL3152635 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL13450787 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL1924296 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL14547320 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL7628296 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL3156153 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL3147308 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL21622002 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR | |
| SCHEMBL121350 | 1.00 | CYP1A2 (0.38) | CYP1A2USP2ALDH1A1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2196201-A2 | Combination of an alpha-2-delta ligand with a pdev inhibitor or a muscarinic antagonist to treat lower urinary tract symptoms | Warner-Lambert Company LLC (US) | 2010-06-16 | — | — | EP | disclosed |